Entos develops Fusogenix DNA vaccine

Entos develops Fusogenix DNA vaccine

Entos Pharmaceuticals has announced the development of a Fusogenix DNA vaccine to prevent COVID-19 infections.

Entos’ Fusogenix platform is a proteo-lipid vehicle (PLV) that uses a novel fusion mechanism to deliver its genetic payload directly inside cells. 

The use of plasmid DNA in a vaccine will allow Entos to design an optimized payload encoding multiple protein epitopes from key immunogenic SARS-COV-2 proteins.

Once the Fusogenix DNA vaccine formulation has been produced it will undergo preclinical testing for safety and efficiency.

Straight Talk

View More